Announcement PDF Neuren Pharmaceuticals Limited Appendix 4C Quarterly report for entities admitted on the basis of commitments ARBN 111 496 130 Rule 4.7B Appendix 4C Quarterly report for entities admitted on the basis of commitments Introduced 31/3/2000. Amended 30/9/2001 Name of entity Neuren Pharmaceuticals Limited ABN Quarter ended (“current quarter”) 72 111 496 130 31 December 2015 Consolidated statement of cash flows Current quarter A$’000 0 Year to date (12 months) A$’000 2,611 (a) staff costs (b) advertising and marketing (c) research and development (d) leased assets (e) other working capital Dividends received Interest and other items of a similar nature received Interest and other costs of finance paid Income taxes (paid)/refunded Other (provide details if material) (538) (4,113) (99) - (1,993) (13,913) (754) - 60 - 363 749 - Net operating cash flows (4,690) (12,937) Cash flows related to operating activities 1.1 Receipts from government 1.2 Payments for 1.3 1.4 1.5 1.6 1.7 + See chapter 19 for defined terms. Appendix 4C Page 1 Appendix 4C Quarterly report for entities admitted on the basis of commitments 1.8 1.9 1.10 1.11 1.12 1.13 Net operating cash flows (carried forward) Neuren Pharmaceuticals Limited ARBN 111 496 130 Current quarter A$’000 Year to date (12 months) A$’000 (4,690) (12,937) Cash flows related to investing activities Payment for acquisition of: (a) businesses (item 5) (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets Proceeds from disposal of: (a) businesses (item 5) (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets - (3) - 4 - 4 - Loans to other entities Loans repaid by other entities Other (provide details if material) - - Net investing cash flows 4 1 1.14 Total operating and investing cash flows (4,686) (12,936) 1.15 1.16 1.17 1.18 1.19 1.20 Cash flows related to financing activities Proceeds from issues of shares, options, etc. Proceeds from sale of forfeited shares Proceeds from borrowings Repayment of borrowings Dividends paid Other 6,510 - 7,549 - Net financing cash flows 6,510 7,549 Net increase (decrease) in cash held 1,824 (5,387) 1.21 1.22 Cash at beginning of quarter/year to date Exchange rate adjustments 15,208 (390) 20,824 1,205 1.23 Cash at end of quarter 16,642 16,642 + See chapter 19 for defined terms. Appendix 4C Page 2 Neuren Pharmaceuticals Limited Appendix 4C Quarterly report for entities admitted on the basis of commitments ARBN 111 496 130 Payments to directors of the entity and associates of the directors Payments to related entities of the entity and associates of the related entities Current quarter A$'000 1.24 Aggregate amount of payments to the parties included in item 1.2 249 1.25 Aggregate amount of loans to the parties included in item 1.11 - 1.26 Explanation necessary for an understanding of the transactions Executive and non-executive directors’ fees paid in the current quarter. Non-cash financing and investing activities 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows N/A 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest N/A Financing facilities available Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2). Amount available $ 3.1 3.2 Amount used $ Loan facilities Credit standby arrangements - - - - + See chapter 19 for defined terms. Appendix 4C Page 3 Appendix 4C Quarterly report for entities admitted on the basis of commitments Neuren Pharmaceuticals Limited ARBN 111 496 130 Reconciliation of cash Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows. Current quarter A$’000 Previous quarter A$’000 4.1 Cash on hand and at bank 4,238 8,654 4.2 Deposits at call 12,404 6,554 4.3 Bank overdraft - - 4.4 Other (provide details) - - 16,642 15,208 Total: cash at end of quarter (item 1.23) Acquisitions and disposals of business entities Acquisitions (Item 1.9(a)) 5.1 Name of entity 5.2 5.4 Place of incorporation or registration Consideration for acquisition or disposal Total net assets 5.5 Nature of business 5.3 Disposals (Item 1.10(a)) N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A Compliance statement 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX. 2 This statement does give a true and fair view of the matters disclosed. .......................................... Jon Pilcher CFO & Company Secretary 29 January 2016 + See chapter 19 for defined terms. Appendix 4C Page 4 Neuren Pharmaceuticals Limited ARBN 111 496 130 Appendix 4C Quarterly report for entities admitted on the basis of commitments Notes 1. The quarterly report provides a basis for informing the market how the entity’s activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report. 2. The definitions in, and provisions of, AASB 1026: Statement of Cash Flows apply to this report except for the paragraphs of the Standard set out below. • • • • • • 3. 6.2 - reconciliation of cash flows arising from operating activities to operating profit or loss 9.2 - itemised disclosure relating to acquisitions 9.4 - itemised disclosure relating to disposals 12.1(a) - policy for classification of cash items 12.3 - disclosure of restrictions on use of cash 13.1 - comparative information Accounting Standards. ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with. + See chapter 19 for defined terms. Appendix 4C Page 5